Multicentre phase II study of the CyclOBEAP regimen for patients with peripheral T-cell lymphoma with analysis of biomarkers

British Journal of Haematology

Volumn 153, Issue 5, 2011, Pages 582-588

  Niitsu, Nozomi ^a   Hayama, Miyuki ^a   Yoshino, Tadashi ^b   Nakamura, Shigeo ^b   Tamaru, Jun Ichi ^b   Nakamine, Hirokazu ^b   Okamoto, Masataka ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Adult Lymphoma Treatment Study Group ALTSG   (Japan)

Author keywords

Chemotherapy; Peripheral T cell lymphoma; Prognostic factor

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; ONCOPROTEIN; PREDNISOLONE; PROTEIN NME1; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ANEMIA; ANGIOIMMUNOBLASTIC T CELL LYMPHOMA; ARTICLE; CARDIOTOXICITY; CONSTIPATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; HEART EJECTION FRACTION; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDEMIOLOGIC METHODS; ETOPOSIDE; FEMALE; HEMATOLOGIC DISEASES; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PREDNISOLONE; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VINCRISTINE; YOUNG ADULT;

EID: 79955725824     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08634.x     Document Type: Article

References (29)

1. Asano, N., Suzuki, R., Kagami, Y., Ishida, F., Kitamura, K., Fukutani, H., Morishima, Y., Takeuchi, K. & Nakamura, S. (2005) Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. American Journal of Surgical Pathology, 10, 1284-1293.
2. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) The international harmonization project on lymphoma. Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
3. Cox, D.R. (1972) Regression models and life tables. Journal of Statistical Society Series B, 34, 187-202.
4. Dupuis, J., Emile, J.F., Mounier, N., Gisselbrecht, C., Martin-Garcia, N., Petrella, T., Bouabdallah, R., Berger, F., Delmer, A., Coiffier, B., Reyes, F. & Gaulard, P.; Groupe d'Etude des Lymphomes de l'Adulte (GELA). (2006) Groupe d'Etude des Lymphomes de l'Adulte (GELA). Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood, 108, 4163-4169.
5. Escalón, M.P., Liu, N.S., Yang, Y., Hess, M., Walker, P.L., Smith, T.L. & Dang, N.H. (2005) Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer, 103, 2091-2098.
6. Gisselbrecht, C., Gaulard, P., Lepage, E., Coiffier, B., Brière, J., Haioun, C., Cazals-Hatem, D., Bosly, A., Xerri, L., Tilly, H., Berger, F., Bouhabdallah, R. & Diebold, J. (1998) Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood, 92, 76-82.
7. Kaplan, E.L. & Meier, P. (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457-481.
8. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Reports, 50, 163-170.
9. Mori, M., Kitamura, K., Masuda, M., Hotta, T., Miyazaki, T., Miura, A.B., Mizoguchi, H., Shibata, A., Saito, H., Matsuda, T., Masaoka, T., Harada, M., Niho, Y. & Takaku, F. (2005) Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. International Journal of Hematology, 81, 246-254.
10. Mourad, N., Mounier, N., Brière, J., Raffoux, E., Delmer, A., Feller, A., Meijer, C.J., Emile, J.F., Bouabdallah, R., Bosly, A., Diebold, J., Haioun, C., Coiffier, B., Gisselbrecht, C. & Gaulard, P.; Groupe d'Etude des Lymphomes de l'Adulte. (2008) Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111, 4463-4470.
11. Niitsu, N., Okabe-Kado, J., Okamoto, M., Takagi, T., Yoshida, T., Aoki, S., Honma, Y. & Hirano, M. (2001) Serum nm23-H1 protein as a prognostic factor in aggressive non-Hodgkin's lymphoma. Blood, 97, 1202-1210.
12. Niitsu, N., Nakamine, H., Okamoto, M., Akamatsu, H., Higashihara, M., Honma, Y., Higashihara, M., Okabe-Kado, J. & Hirano, M. (2004) Clinical significance of intracytoplasmic nm23-H1 expression in diffuse large B-cell lymphoma. Clinical Cancer Research, 10, 2482-2490.
13. Niitsu, N., Okamoto, M., Aoki, S., Okumura, H., Yoshino, T., Miura, I. & Hirano, M. (2006) Multicenter phase II study of the CyclOBEAP (CHOP-like+etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma. Annals of Hematology, 85, 374-380.
14. Niitsu, N., Okamoto, M., Nakamine, H., Aoki, S., Motomura, S. & Hirano, M. (2008a) Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. Hematological Oncology, 26, 152-158.
15. Niitsu, N., Nakamine, H., Okamoto, M., Tamaru, J.I. & Hirano, M. (2008b) A clinicopathological study of nm23-H1 expression in classical Hodgkin lymphoma. Annals of Oncology, 19, 1941-1946.
16. Niitsu, N., Kohri, M., Hagiwara, Y., Tanae, K., Takahashi, N., Bessho, M. & Okamoto, M. (2010) Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma. Hematological Oncology, 28, 68-74.
17. Pfreundschuh, M., Trumper, L., Kloess, M., Schmits, R., Feller, A.C., Rudolph, C., Reiser, M., Hossfeld, D.K., Metzner, B., Hasenclever, D., Schmitz, N., Glass, B., Rübe, C. & Loeffler, M. (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood, 104, 626-633.
18. Reimer, P., Rudiger, T., Geissinger, E., Eissinger, F., Nerl, C., Schmitz, N., Engert, A., Einsele, H., Müller-Hermelink, H.K. & Wilhelm, M. (2009) Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. Journal of Clinical Oncology, 27, 106-113.
19. Rodriguez, J., Conde, E., Gutierrez, A., Arranz, R., León, A., Marín, J., Bendandi, M., Albo, C. & Caballero, M.D.; Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO). (2007) Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo study group. European Journal of Haematology, 79.32-38.
20. Rudiger, T., Weisenburger, D.D., Anderson, J.R., Armitage, J.O., Diebold, J., MacLennan, K.A., Nathwani, B.N., Ullrich, F. & Müller-Hermelink, H.K. (2002) Non-Hodgkin's lymphoma classification project. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the non-Hodgkin's lymphoma classification project. Annals of Oncology, 13, 140-149.
21. Savage, K.J. (2008) Prognosis and primary therapy in peripheral T-cell lymphomas. American Society of Hematology Education Program, 1, 280-288.
22. Schmitz, N., Ziepert, M., Nickelsen, M., Nickelsen, M., Ho, A.D. & Metzner, B. (2008) T-cell lymphomas in studies of the German high-grade NHL study group (DSHNHL). Annals of Oncology, 19, (Suppl. 4), 113, Abstract 094.
23. Shipp, M.A. (1993) International non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive non-Hodgkin's lymphoma. New England Journal of Medicine, 329, 987-994.
24. Simon, A., Peoch, M., Casassus, P., Deconinck, E., Colombat, P., Desablens, B., Tournilhac, O., Eghbali, H., Foussard, C., Jaubert, J., Vilque, J.P., Rossi, J.F., Lucas, V., Delwail, V., Thyss, A., Maloisel, F., Milpied, N., le Gouill, S., Lamy, T. & Gressin, R. (2010) Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. British Journal Haematology, 151, 159-166.
25. Steeg, P.S., Bevilacqua, G., Kopper, L., Thorgeirsson, U.P., Talmadge, J.E., Liotta, L.A. & Sobel, M.E. (1988) Evidence for a novel gene associated with low tumor metastatic potential. Journal of the National Cancer Institute, 80, 200-204.
26. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E., Pileri, A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoidtissues, 4th edn. IARC Press, Lyon, France.
27. Tilly, H., Lepage, E., Coiffier, B., Blanc, M., Herbrecht, R., Bosly, A., Attal, M., Fillet, G., Guettier, C., Molina, T.J., Gisselbrecht, C. & Reyes, F. (2003) Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood, 102, 4284-4289.
28. Vose, J., Armitage, J. & Weisenburger, D. (2008) International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. Journal of Clinical Oncology, 26, 4124-4130.
29. Wilcoxon, F. (1945) Individual comparisons by ranking methods. Biometrics Bulletin, 1, 80-83.